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Abstract
Purpose Desmoid fibromatosis (DF) is a rare, unpredictable disease with no established, evidence-based treatments. Individual
management is based on consensus algorithms. This study aimed to examine the specific health-related quality of life challenges
faced by DF patients, current experiences and expectations of care.
Methods Twenty-seven DF patients were purposively sampled from The Royal Marsden Hospital. Two focus groups and 13
interviews (males 12, females 15; mean age at study 39.5 years) explored health-related quality of life issues and experiences of
healthcare. Thematic content was analysed.
Results Discussions revealed four key themes (diagnostic pathway; treatment pathway; living with DF; supportive care).
Diagnostic delay resulted from lack of recognition by patients and healthcare professionals. Some patients received an initial
diagnosis of cancer, causing significant distress. Treatment decisions were challenging, and patients experienced uncertainty
among clinicians about optimal therapies. Side-effects of treatment were severe, including fatigue, nausea, anorexia, low libido
and depression. Pain was the most debilitating symptom and dependency on painkillers was a significant concern. Functional
limitation and restricted mobility frequently affected daily activities. Patients experienced difficulty accomplishing their role in
society; relationship problems, caring for children, employment and financial difficulties. Social isolation and lack of under-
standing were common. The psychological impact of this Blife-changing and life-long^ condition was profound. All patients
requested knowledgeable healthcare professionals, more information, continuity of care and peer support.
Conclusions DF patients face complex physical, psychological and practical challenges. Comprehensive care services are need-
ed. Increasing awareness may help to improve diagnostic pathways and overall patient experience.
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Introduction
Desmoid-type fibromatosis (DF) is a rare, difficult to manage
mesenchymal tumour, which accounts for 3% of soft-tissue
tumours [1, 2]. The reported incidence is 2–4 individuals per
million per year [3]. DF usually affects patients aged between
15 and 60 years, with a peak around 30 years [4].
Approximately 85–90% of cases are associated with muta-
tions in the β-catenin gene (CTNNB1), leading to accumula-
tion of β-catenin protein [5]. In a minority of cases (5–10%),
DF can arise in the context of familial adenomatous polyposis
(FAP) [5]. Tumours can originate in almost any area of the
body, most frequently extremities, trunk, abdominal cavity,
abdominal wall, head and neck [5, 6]. Although not by defi-
nition ‘malignant’, the morbidity caused by this disease and its
associated treatments is far from ‘benign’ [7]. The clinical
course varies; tumours may progress rapidly, remain stable
for many years or undergo spontaneous regression [8, 9].
Furthermore, there is no linear relationship between symp-
toms and size of DF lesions.
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Due to its heterogeneous behaviour, there are no
established, evidence-based treatment guidelines and deci-
sions are based on consensus recommendations [5, 6].
Treatment options include surgery, radiotherapy, chemothera-
py, hormonal agents and non-steroidal anti-inflammatory
drugs (NSAIDS) [5, 6]. The marginal clinical benefit of these
treatments coupled with potentially serious adverse effects
leads to challenging management decisions. Angiogenesis in-
hibitors, such as pazopanib, have shown activity in a small
case-series, however, have yet to be validated in larger clinical
trials [10]. More recently, the gamma-secretase inhibitor PF-
03084014 has shown promising activity with clinically mean-
ingful symptomatic benefit and durable responses in small
numbers of patients [11, 12]. The optimum duration of sys-
temic therapy remains undefined, and there are issues related
to access and reimbursement of novel agents, which inevitably
play an important role in the management of specific patients.
Over the past decade, most specialist centres have moved
away from primary surgery towards a first-line ‘watch-and-
wait’ policy for asymptomatic tumours. In contrast to radical
and often mutilating surgery, preservation of function and
avoiding disfiguring outcomes has become a priority in the
management of DF patients [5, 6].
Although desmoid tumours are incapable of metastasiz-
ing (often described as benign disease), patients some-
times undergo treatments similar to cancer patients, and
experience symptoms of pain and reduced mobility and/or
ability to carry out everyday activities. However, the pa-
tient’s health-related quality of life (HRQoL) has not been
studied extensively. The care for DF patients may be com-
promised by a lack of insight into the physical, psycho-
social and practical challenges they encounter. In order to
optimise supportive care services, we must gain better
understanding of the DF patient journey. Therefore, the
aims of this study were to examine the specific challenges
faced by DF patients, current care experiences and expec-
tations of care.
Methods
Sample and procedure
Adult DF patients were recruited from the Royal Marsden
Hospital sarcoma outpatient clinic. Patients were eligible
if they were (1) aged ≥ 18 years; (2) diagnosed with his-
tologically proven DF (primary or recurrent disease, any
primary location, any management plan including active
surveillance); and (3) could communicate in English.
Patients with significant cognitive impairment or mental
health problems, as determined by the referring HCP,
were excluded. We employed purposive sampling to
obtain a varied sample with regard to age and tumour
localization.
The medical consultant, clinical nurse specialist or
physiotherapist offered potential participants an informa-
tion letter. With their permission, a member of the re-
search team (OH/EY) contacted them to ask if they were
willing to participate. Two focus group meetings of
120 min were scheduled at the hospital and interviews
were conducted until saturation (no new topics appeared)
was reached. Patients for the interviews were recruited
according to an inductive design, indicating that the re-
sults of the focus groups and previous interviews shaped
the recruitment for the next interviews. All participants
gave written informed consent prior to the focus group
or interview. Participants completed demographic, clinical
and HRQoL questions before the focus group or inter-
view. HRQoL was assessed with the EORTC QLQ-C30
[13]. This contains five functional scales (physical, role,
cognitive, emotional and social functioning), a global
health status/QoL scale, three symptoms scales (fatigue,
nausea/vomiting, pain) and six single items assessing dys-
pnea, insomnia, anorexia, constipation, diarrhoea, and fi-
nancial impact. Each item is scored on a 4-point Likert-
scale, except general QoL, which has a seven-point
Likert-scale. Scores were linear transformed to a 0–100
scale [14]. Higher score on functional scales and general
QoL scale means better functioning and HRQoL, whereas
a higher score on the symptom scales mean more com-
plaints. Although developed for cancer patients, these
questions can be appropriate for any respondent, e.g.
‘Do you have any trouble taking a long walk’ (physical
functioning). The study was deemed exempt from full
review and approval by a research ethics committee
(CCR the Royal Marsden Hospital), but was approved
by the service evaluation committee of the Royal
Marsden Hospital (SE606).
Focus groups and interviews
Two focus groups and 13 interviews were conducted by two
members of the research team (EY and OH). A semi-
structured interview schedule was used (Attachment 5).
Topics and questions were based on clinical experience and
literature [5, 6].
Data analysis and reporting
The consolidated criteria for reporting qualitative research
(COREQ) were followed to ensure accuracy of this qual-
itative study. The interviews were transcribed smooth ver-
batim using F4 software. Data analysis was conducted by
two coders (OH and EY) via ATLAS.ti 8.0 using thematic
analysis [15, 16]. Both coders read the transcripts several
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times, highlighted sections that were related to the re-
search objectives, independently selected and coded these
into key themes and subthemes. Thereafter, the coders
discussed their findings, refined the key themes and sub-
themes, and resolved differences until consensus was
reached. All quotes were anonymised.
Results
Participants
Twenty-seven patients participated (14 in focus groups
and 13 interviews). Sociodemographic and clinical char-
acteristics are presented in Table 1. DF patients scored
low on all functioning scales (physical 74.4; role 55.8;
social 52.8; cognitive 70.1; and emotional 56.9) and
global QoL scale (56.9) of the EORTC QLQ-C30 and
exceptionally high on the symptom scales pain (59.0),
insomnia (56.9), fatigue (53.6) and financial difficulties
(31.9).
DF patient journey
Analysis of the transcripts resulted in 4 main themes (diagnos-
tic pathway; treatment pathway; living with DF; supportive
care) and 12 subthemes (Fig. 1).
Diagnostic pathway (Appendix 1)
Most DF patients reported delay in diagnosis. Patients
frequently did not recognise the serious nature of their
own symptoms. In addition, patients experienced a long
diagnostic trajectory within primary and secondary
healthcare accompanied by frustration and uncertainty.
Patients felt that their symptoms were not taken seriously
and were transferred from ‘hospital to hospital to hospi-
tal’ to receive the correct diagnosis of DF. Several pa-
tients were initially given a diagnosis of ‘cancer’ or ‘ma-
lignant sarcoma’ and informed that the anticipated prog-
nosis was bleak. These patients experienced shock and
distress due to a cancer diagnosis and the ordeal of shar-
ing this news with their families. Others found that re-
ceiving an incorrect diagnosis of cancer resulted in mean-
ing-making, leading them to reassess the direction of
their lives and consider positive lifestyle choices such
as applying for a ‘dream job’ or instigating a ‘health
kick’.
Treatment pathway (Appendix 2)
DF patients experienced uncertainty among clinicians
about the optimal sequence of therapies. Patients found
Table 1 Sociodemographic and clinical characteristics of study
participants
Sociodemographic characteristics
Age time diagnosis—mean (SD; range) 34.1 (15.5; 11–70)
Age at time study—mean (SD; range) 39.5 (13.7; 23–74)
Sex, N (%)
Male 12 (44.4%)
Female 15 (55.6%)
Ethnic background, N (%)
White 21 (77.8%)
Mixed 2 (7.4%)
Black or black British 2 (7.4%)
Chinese 1 (3.7%)
Other 1 (3.7%)
Relationship status, N (%)
Single 5 (18.5%)
Dating/in a relationship 8 (29.6%)
Married 10 (37.0%)
Living common 3 (11.1%)
Separated 1 (3.7%)
Caring responsibilities children under 18 years, N (%)
Yes 9 (33.3%)
No 18 (66.7%)
Highest formal education, N (%)
Less than compulsory school 1 (3.7%)
Compulsory school 1 (3.7%)
Further education 9 (33.3%)
Higher education—undergraduate 7 (25.9%)
Higher education—postgraduate 7 (25.9%)
Professional qualification 1 (3.7%)
Other 1 (7.1%)
Employment status, N (%)
Employed full-time 14 (51.9%)
Employed part-time 5 (18.5%)
Looking after home or family 2 (7.4%)
On temporary medical leave/disability 3 (11.1%)
Unemployed 2 (7.4%)
Missing 1 (3.7%)
Clinical characteristics (self-report)
Location of desmoid, N (%)
Abdominal wall 3 (11.1%)
Intra-abdominal 3 (11.1%)
Retroperitoneal/pelvic 3 (11.1%)
Extremity/girdles/chest wall 11 (40.7%)
Head and neck/intrathoracic 3 (11.1%)
Shoulder/scapula 4 (14.8%)
Treatment received, N (%)
Watch and wait policy 9 (33.3%)
Surgery 12 (44.4%)
Radiotherapy 6 (22.2%)
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decisions challenging, including potentially debilitating
surgery, radiotherapy or cytotoxic chemotherapy without
clear evidence of treatment effectiveness. Several patients
felt that there was a lack of guidance from healthcare
professionals (HCP) about the most appropriate treatment
and desired someone with knowledge and experience to
make the best decision on their behalf. With the benefit of
hindsight, some patients would have made different deci-
sions and may have benefited from talking to others with
DF. Treatment-related side effects were common and se-
vere. Patients reported profound fatigue, loss of concen-
tration, daily nausea, vomiting and loss of appetite, lack
of l ib ido and depress ion . Those who rece ived
chemotherapy suffered from ‘horrendous’ side effects in-
cluding mouth ‘blisters’, ‘vomiting daily’ and ‘feeling like
death’. Radiotherapy induced pulmonary fibrosis caused
‘life-changing’ breathlessness on minimal exertion.
Living with desmoid-type fibromatosis (Appendix 3)
Pain was the most debilitating symptom mentioned by all
patients. Dependency on painkillers was a significant con-
cern for several patients and others found that pain was
unresponsive to analgesics. Patients reported functional
limitation due to pain and restricted mobility, affecting
daily activities such as bathing, dressing and carrying
children. Others had to give up hobbies such as horse
riding and rock-climbing. The unrelenting nature of pain
and its impact on patients’ lives led to substantial psycho-
logical distress.
In addition to physical limitations, DF patients expe-
rienced difficulty accomplishing their role in society. The
side effects of treatment and long-term effects of the
disease caused relationship problems for several patients.
Loss of libido affected sexual relationships and some
reported break-down of their relationship or marriage.
Patients did not want to feel as though they were a bur-
den on their partner or family and tried to cope alone.
DF patients also felt that their parental role was affected
including difficulty breastfeeding, playing games with
their children and depending on their partner or parent
for childcare. Others felt guilty, as they did not want to
burden their parents, siblings or children to the detriment
of other family members. Suicidal thoughts were
expressed by those who found the burden too much to
bear (N = 3).
DF patients experienced changes to their employment
due to their disease and found it frustrating being unable
to work and wanting to feel ‘normal’. Some patients felt
discriminated due to enforced sick leave, which was
demoralising and led to loss of progression within their
job role. In addition, financial difficulty resulting from
loss of employment and hospital travel expenses was a
significant concern for several patients.
Patients felt that those around them had difficulty un-
derstanding their disease, leading to frustration. At times,
if not receiving active treatment, others perceived that the
disease was not ‘serious’ and patients described that con-
cern went ‘away when it’s not malignant’. Social isolation
was considerable and many felt ‘alone’. Patients also felt
socially behind their peers, who had greater confidence
due to more experiences.
Patients described the psychological demands of living
with a chronic disease that is ‘life-changing and life-long’.
The uncertain behaviour of DF and fear of recurrence
were mentioned by most patients. Others felt hyper-
Table 1 (continued)
Sociodemographic characteristics
Chemotherapy 11 (40.7%)
NSAIDS 4 (14.8%)
Hormonal treatment 10 (37.0%)
TKI 2 (7.4%)
Pain management 10 (37.0%)
Physiotherapy 6 (22.2%)
Occupational therapy 2 (7.4%)
Recurrent disease, N (%)
Yes 11 (40.7%)
No 16 (59.3%)
Comorbid disease, N (%)
None 9 (33.3%)
One 15 (55.6%)
Two or more 3 (11.1%)
Health-related quality of life functioning scores 0–100—mean (SD)a
Global quality of life 56.9 (22.9)
Physical functioning 74.4 (24.4)
Role functioning 55.8 (37.8)
Social functioning 52.8 (40.4)
Cognitive functioning 70.1 (29.5)
Emotional functioning 56.9 (27.2)
Health-related quality of life symptom scores 0–100—mean (SD)b
Fatigue 53.6 (36.2)
Nausea 13.2 (19.6)
Pain 59.0 (39.6)
Dyspnea 19.4 (32.5)
Insomnia 56.9 (42.2)
Appetite 14.5 (22.1)
Constipation 16.7 (31.1)
Diarrhoea 16.7 (29.5)
Financial difficulties 31.9 (33.3)
a Higher scores indicate better functioning
bHigher scores indicate more symptoms
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vigilant to any changes in pressure, sensation or pain,
worrying that this signified deterioration in their disease.
Negative body image was common, especially among
women who felt ‘less feminine’ due to lumps or surgical
scars. Many patients experienced depression and negative
thoughts due to their disease and treatment, feeling ‘down
and down and down’ and describing that they could not
‘be in that state forever’. Mood changes were common
among patients.
Supportive care (Appendix 4)
All patients found it frustrating that many HCP lacked
knowledge about their rare disease. Many wanted a con-
cise information leaflet that they could present to their
friends, family and others. Although treatments were sim-
ilar to cancer patients, almost all patients felt that there
was no specific support available for them and were
turned away by cancer charities and organisations.
Results
Theme 1: Diagnosc pathway
Subtheme 1: Delay in diagnosis
Category 1: Paent delay
Category 2: Doctors’ or health care system delay - symptoms not taken 
seriously
Subtheme 2: Wrong diagnosis
Category 1: Negave experience
Category 2: Posive experience – meaning making
Theme 2: Treatment pathway
Subtheme 1: Treatment decision making
Subtheme 2: Direct treatment side effects
Theme 3: Living with desmoid-type fibromatosis
Subtheme 1: Physical funconing
Category 1: Pain and discomfort
Category 2: Dependency on pain-killers
Category 3: Funconal limitaons because of pain
Category 4: Mobility
Subtheme 2: Role limitaons
Category 1: Marital funconing
Category 2: Family funconing
Category 3: Job/finances
Subtheme 3: Social funconing
Category 1: Lack of understanding
Category 2: Social isolaon
Subtheme 4: Emoonal funconing
Category 1: Living with a chronic disease
Category 2: Uncertainty – tumor behavior - recurrence
Category 3: Mood
Category 4: Body image
Theme 4: Supporve care
Subtheme 1: Finding your way in the health care system with a rare disease
Subtheme 2: Informaon provision
Subtheme 3: Connuity of care
Subtheme 4: Peer support
Fig. 1 Schematic representation
of main findings
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Being treating in a cancer-specific hospital, patients felt
uncomfortable, like ‘a fraud’, as if they would ‘waste
time’ because others may have ‘terminal conditions’.
Several patients indicated that the information provision
by HCP was largely missing or could be improved.
Patients were frustrated by lack of continuity and differ-
ing opinions offered by clinicians at each hospital ap-
pointment. Patients indicated that adequate psychological
support was not accessible and felt it would be
comforting to meet others with the same condition, whom
they could contact for support and advice. They consid-
ered that face-to-face contact or online groups would be
useful.
Discussion
In the present study, we found that DF patients experi-
enced many challenges related to their diagnosis and
treatment. The most commonly reported difficulties were
delayed diagnosis, treatment uncertainty, treatment-related
side-effects, debilitating symptoms, resulting in limita-
tions in physical and psychosocial functioning, and finan-
cial challenges.
Most patients described a prolonged diagnostic path-
way. Diagnostic delay is a common feature of rare dis-
eases, such as DF, whereby the low prevalence leads to
reduced public awareness, and lack of expertise outside
specialist centres [17]. Patients’ health-seeking behav-
iours are complex and can be influenced by physical,
social and psychological factors [18]. The clinical pre-
sentation of DF is variable. Non-specific symptoms
(e.g. pain or swelling) and very low prevalence are as-
sociated with diagnostic difficulty and error in primary
care [19]. Most soft tissue lumps are not ‘aggressive’ or
malignant, and therefore clinical suspicion among HCP
may be low [20]. It is not known whether diagnostic
‘delay’ influences overall outcomes for DF patients;
however, it is undeniable that a lengthy diagnostic path-
way can cause significantly psychological morbidity.
Duration of diagnostic delay has been shown to be pos-
itively correlated with psychological distress among can-
cer patients [21]. Several DF patients received an initial
diagnosis of ‘cancer’ which caused significant anxiety.
Others found that confrontation with a potentially life-
threatening disease provided meaning-making, prompting
them to make positive changes to their lives. Regrettably,
inaccurate diagnosis is not uncommon; a retrospective
review of 320 specimens from DF patients found that
up to one third of cases were incorrectly ascribed a di-
agnosis of DF [22].
Greater awareness of DF is needed among the public
and HCP. The analogy of a ‘golf-ball’ has been used to
increase awareness of the potentially serious nature of soft
tissue lumps for soft tissue sarcomas [23]. HCP should
also have easily accessible, accurate information to im-
prove early diagnosis and provide appropriate support to
patients and their families [17].
Patients reported that uncertainty among HCP about
the optimal treatment strategy led to anxiety and loss of
confidence in HCP. Due to the rarity of DF and lack of
known meaningful endpoints, randomised phase 3 clinical
trials have not been possible thus far [5]. In keeping with
the standard oncological approach, most randomised
phase 2 studies evaluate treatment-efficacy based on ra-
diological endpoints and may not include other aspects
which are relevant to the DF patient’s well-being [24,
25]. Consensus guidelines, based on best available evi-
dence, aim to clarify and unify the approach to the man-
agement of DF [5]. An initial watchful waiting period is
recommended followed by a multidisciplinary treatment
plan for those with clearly progressive disease [5, 26].
Watchful-waiting is associated with uncertainty, fear,
stress and anxiety in patients with cancer and other non-
malignant conditions [27].
Patients who received an array of anti-cancer therapies
reported that side-effects were underplayed by HCP.
Discrepancy between patient reported outcomes and
clinician-assessed toxicity has been well-described in pa-
tients treated with anti-cancer therapies [28]. Clinicians
frequently underestimate the frequency and severity of
side-effects which can lead to inadequate supportive care
[29]. Coping with the uncertainty of treatment efficacy
combined with the unpredictable natural history was ex-
tremely difficult. The treatment of rare diseases such as
DF is challenging. Therapeutic options are often expen-
sive and lack investment from pharmaceutical companies
due to the small potential market. A number of drugs for
DF patients, including gamma-secretase and tyrosine ki-
nase inhibitors have shown promise in early phase clinical
trials, and comparative, randomised data are needed [5].
Defining the optimal, clinically meaningful, endpoint of
such studies will be challenging. Unfortunately, tyrosine
kinase inhibitors that have shown benefit, are not easily
accessible for DF patients as they are not licenced or
reimbursed in all European countries [5]. In the absence
of validated predictive factors, an individualised approach
is recommended for all DF patients [26]. The risks and
benefits of treatment should be carefully considered, inte-
grating tumour location and characteristics with individual
patient factors and preferences. Routinely measuring
HRQoL in clinical practice and in research trials will lead
to a better understanding of treatment efficacy from the
patient perspective.
Due to the low prevalence and the lack of expertise DF
patients are forced to become Bknowledgeable^ experts
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about their own disease. Appropriate information is large-
ly lacking and should be developed. Careful counselling
at a specialist centre, where HCP have knowledge about
DF, is mandatory and should be offered to all patients
affected by DF from the time of their diagnosis [5, 6].
Treatment and follow-up at a specialist centre will also
improve the continuity of care.
Pain was the most debilitating symptom among DF pa-
tients. The mechanisms of pain in DF are complex and
multifactorial and there is no direct correlation between
pain and disease progression [5, 6]. Pain also commonly
affects daily functioning in cancer survivors, especially in
the first few years after treatment [30]. Numerous recom-
mendations, which have been made to reduce pain in can-
cer survivors, may also be applicable to DF patients, in-
cluding pain-screening and pharmacotherapy [31–34]. Due
to the chronicity of DF, there is concern about the long-
term adverse effects of painkillers, risks of misuse, over-
dose and addiction. In our study, some DF patients felt
physically and psychologically dependent on painkillers.
As with chronic, non-malignant pain, multimodal interven-
tions that incorporate non-pharmacological therapies could
be integrated into therapy for DF patients, aiming to restore
functionality where possible.
This study showed that DF can have a considerable
impact on relationships, social roles and functioning. A
diagnosis of DF and/or its treatment affected finances
and employment, through a reduced ability to work, need
to adapt roles in the workplace and sometimes even job
loss. Patients also voluntarily changed employment after
self-reflection about life’s priorities. The ability to work
following DF is important for maintaining self-respect,
identity and living conditions [35]. Financial strain due
to lost productivity and medical costs, including travelling
costs to the hospital can lead to dependence on family
members and have an adverse effect on patients’ social
relationships.
Patients do not want to burden their partner, family or
friends. DF patients sometimes feel isolated and miss out
on important social activities. Most people have little fa-
miliarity with the physical and psychosocial impact of DF
and may not know how to support a patient. Taking into
account the relatively young patient population, patients
should be supported to maintain a ‘normal’ life [5, 6].
In addition to Bcuring^ the disease, the imperative
long-term goal of any treatment strategy for DF should
include maintenance or reintegration of a patient to social
and work roles as far as possible. Interventions that pro-
mote social integration for DF patients (e.g. psychological
and social support) and vocational counselling seem
indicated.
Improved peer support may have helped DF patients to
relate their experience to that of others with the same
disease. For example, (online) peer-support groups and
disease-specific information portals for patients with other
rare disease have been shown to significantly reduce feel-
ings of social isolation, improve knowledge, self-efficacy,
problem-solving skills and effective interpersonal interac-
tions [36–38]. The Royal Marsden Hospital is developing
a regular clinic specifically for DF patients, which will
also enable patients to meet each other at the hospital.
In addition, multi-disciplinary support, involving pain
specialists, physiotherapists, social workers and psychol-
ogists, should be offered to DF patients when indicated.
Many patients in our study felt uncomfortable that they
had to attend a clinic for patients with cancer and there-
fore a dedicated monthly multidisciplinary clinic (depend-
ing on the local resources) may provide a more suitable
environment for their outpatient appointments.
Several limitations of this study should be taken into
account. Firstly, most participants received some form of
treatment and therefore may not adequately reflect the full
range of DF patients. Patients on a watch and wait policy
may have less problems and no treatment-related side ef-
fects. In addition, data on ethnic background were lack-
ing, there were no Afro-Caribbean and Asian participants.
Due to the limited number of patients, we could not ex-
amine gender differences with statistical probability; how-
ever, generally female patients had more problems with
body image and talked more about what other people
thought about their disease, while males reported uncer-
tainty about disease growth or recurrence more often. In
addition, our study sample may reflect patients who feel
comfortable talking about their patient journey. We relied
on patient self-report for the clinical characteristics of
their disease. Our results should also be interpreted in
the context of financial constraints of the UK National
Health Service (NHS): leading to reduced access to cer-
tain drugs (e.g. pazopanib).
Further research is needed, preferably an international,
population-based study which will integrate patient-
reported outcome data with objective clinical examina-
tion, radiological findings and potentially molecular char-
acteristics. This will allow greater insight into potential
prognostic factors, treatment efficacy from the patients’
perspective and enable provision of a more holistic ap-
proach to care. Overall, DF patients face complex physi-
c a l , p s y cho l og i c a l a n d p r a c t i c a l c h a l l e ng e s .
Comprehensive services including improving peer-
support networks are needed. Increasing awareness of this
debilitating disease may also help to improve diagnostic
pathways and overall patient experience.
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Subtheme 1: Delay in diagnosis
Category 1: Paent delay
It was the size of the thing growing. That's how I really realised there's something wrong. It sounds trivial but my trousers
wouldn't fit. And I hadn't got any clothes that would go round this lump. We didn't know what it was. I thought I was 
geng fat. So, you do what you can to try and lose weight. (Female, 71)
I went to the GP because I start looking a lump in my chest. I was working as a beaucian at the beginning so I thought 
'cause my work, this happens. It's a muscle that is developing there. So I thought, okay. So I was dealing six months with 
the same thought that it is the muscle. (Female, 32)
So when I eventually went to my GP 'cause I'd just watched this thing grow for years. (Female, 28)
So, originally I just had a small lump in my arm that I did nothing about for a couple of months and then my wife told me 
to go to the doctor’s. (Male, 40)
Category 2: Doctors’ or health care system delay - symptoms not taken seriously
So it took a long, long me to diagnose…. The diagnosis took a year. And I was shipped from hospital to hospital to 
hospital. (Female, 25)
The obvious thing that was distressing was the diagnosis took forever at a regional hospital. And they hadn't a clue what 
they were looking at really. The anxiety that went along with that was quite difficult to bear. (Female, 71)
But going back to one of the points that you guys made as well, about the poo-pooing what it was, I actually felt the first 
lump when I was 14, in the back of my leg. And the doctor went, “Oh, it’s a cyst, don’t worry about it.” A year later it’d 
got to the size of an egg and it was only the fact that my mum took me to the A&E that they dealt with it. (Male, 45)
And I went to the doctors and they said, oh, it's growing pains. I was 18 years of age. They were like, well, maybe it's just 
your natural growth. It's just like, you get made to think you're making it up. And then they sent me for X-rays, but didn’t 
show anything. And it was when I was about 20, just before my 21st birthday, my dad took a picture of me in a ght top. 
He said, no, there is something there. Take that picture to the GP. I showed the GP and she went,  oh, I'll refer you if you 
want to. We have to give you an appointment within 16 weeks. In 16 weeks you could be dead. So I actually had to pay to 
see the same consultant private. But it is the best 150 pounds I have ever spent. (Female, 32)
On MRI they didn’t see that it was Fibromatosis, they said it was muscle wastage. They said “That’s fine, don’t worry 
about it, just massage it.” So, I was massaging it for about a year as much as I could and then it [pain] became totally 
unbearable and then I had the referral to The Royal Marsden Hospital and received the diagnosis of Fibromatosis.(Male, 
40)
Subtheme 2: Wrong diagnosis
Category 1: Negave experience
So just went to the GP and they sent me for some scans and, in fact, phoned me up and told me it was cancer, Sarcoma, 
so actually said I had cancer. So originally I was under the impression that it was a more serious condion than 
Fibromatosis in the comparable sense. So obviously that first diagnosis of having cancer was quite a shock to obviously 
tell your family and everything and go through all of that. (Male, 40)
And she [consultant] said we think you've got a malignant sarcoma. And the treatment we're going to have to give you, 
your baby probably won't survive. And then she said the survival rate for you aerwards isn't necessarily that great. But 
then I got referred The Royal Marsden and they took biopsies. I saw Dr. Hayes and he said... We were talking through 
stuff and then he said... I menoned that I was pregnant and he went, oh, you're pregnant. He said, well, it's almost 
definitely fibromatosis then. And that completely changed everything. It was all quite a bit of a whirlwind experience.
(Female, 28)
Category 2: Posive experience – meaning making
Because, obviously, when I was first diagnosed, I thought it was sarcoma. So I thought I was going to die. And that really 
made me reassess my life. Realised I didn't want to die whilst doing my current job. So I, basically, applied for my dream 
job. And I'm moving on towards the career that I want. So it gave me quite a healthy kick really. So that has been the 
posive element. (Female, 38)
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Subtheme 1: Treatment decision making
The choice of surgery or radiotherapy, obviously they talk about the ladder of starng with Tamoxifen and various types 
of chemo, radiotherapy, surgery. Surgery is always seen as the last result, or the end game kind of thing. But obviously 
the risks of radiotherapy for a younger person and obviously the amount of mes you can probably have it in your life, 
versus potenally the debilitang outcome of surgery, was a very difficult decision to make….So, we were in a bit of a, 
“What do we do?” It was very much posed as, “You decide,” and I was like, “I don’t know what I’m supposed to do.” So 
we were in this posion of looking for some guidance of what we should do at that stage.(Male, 40)
Because when I started on the treatment ladder I was told, “We’ll start at the boom rung, we’ll move up through the 
treatment.” With hindsight, and I remember thinking it at the me as well, when I was first diagnosed the lump was very, 
very small. By the me last year, when I had the operaon, it was a very big tumour. There is obviously a huge risk of 
operang and it returning and stuff, but to operate on something that was that big at the me….. it would have been a 
much smaller one than ulmately spending three or so years of my life having prey horrible treatment and sll ending
up having an operaon which was obviously a much bigger operaon. Just my story looking back, I potenally might 
have made different decisions at different mes and being able to speak to people around potenally what would 
happen if I was going to do this drug for so long or whatever, would have been really valuable. (Male, 36)
But then it was going through that process of how are we going to treat it. I was saying, just let me get through my 50th
birthday. Let me have that at least. And then, having the chemotherapy, which then didn't shrink the tumour and really 
didn't have that much effect on it. (Female, 59)
They don't want to frighten people. And you think you've got to take it and all the rest of it but then you don't realise 
that's why you feel like you feel. (Female, 71)
Because I was 23, 24 and just had a baby and everything. I didn't really want to make my own decisions. I didn't feel like I 
had the right experience behind me or knowledge behind me. And I was quite happy for someone to sit there and say, we 
think this is the best opon for you at the moment. (Female, 28)
There is a lack of consistency in treatment recommendaons between different consultants and different teams (pain 
management team, sarcoma team). I chose to assess the situaon myself and since no clear and consistent course of 
treatment plan was offered that I felt secure and comfortable with, I decided to withdraw from all medicaon. (Female, 
30)
Subtheme 2: Direct treatment side effects
It’s when you’re in the middle of it [Tamoxifen], two years down the line or whatever it is and you’re feeling like death.
(Female, 71)
I was being sick daily because of complicaons with my medicaon. So I had a big period of sickness, I was nauseous and 
so on, and I lost a lot of weight last year, obviously not feeling, having much of an appete. (Female, 38)
The year I had the chemotherapy, that was probably the worst year of my life. I don’t think I’d wish that Caelyx
chemotherapy on my worst enemy. I was horrendously ill. I didn’t quite have appendicis but I was prey bad and the 
side effects were horrendous eczema all over my body and they took me off aer ten doses. (Male, 45)
Started on Tamoxifen which is an evil drug. Like these gentlemen here, again, lack of libido, nausea. You don’t feel 
yourself and, yes, it wasn’t nice for that period of me…. The side effects of Pazopanib, it made me very sick and fagued.
So I was knackered all the me. Interesngly, it turned my hair white….. From the Caelyx I was very red, very fagued, 
but I think what made it worse was the increase in painkillers I was taking. So, I was upping the amount of Pregabalin, 
morphine, to a very, very high dosage, and that also really didn’t help to my aenon levels, concentraon, fague was 
awful. So I wasn’t sleeping, it was all kind of a Catch 22 circular effect. (Male, 40)
My side-effects were really bad. I had hives all over. It was bleeding. (Female, 28)
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Subtheme 1: Physical funconing
Category 1: Pain
And I sat here with my consultant and I just burst... I went, I cannot deal with this pain any more. (Female, 28)
I suffered from a lot, lot, lot of pain. (Female, 25)
Yes. Well, the pain is probably now the worst thing about it. It seems not to respond to anything, the pain. (Male, 40)
So, it felt like a burn. It was like a bad bruise that someone was always pressing on and then as it grew bigger it pressed 
on the nerves and I’d get the snging, stabbing pains. But the pain I had, it was really sensive so even just wearing 
clothes and stuff it would hurt. (Male, 40)
That snging pain. I’ve got to points where I’d quite happily take a serrated kitchen knife and cut my own leg off, it was 
that bad. (Male, 45)
Category 2: Dependency on pain-killers
I’ve been taking Tramadol for seven years and my body is totally hooked on them. You are like cold turkey, if it’s not in 
your system it’s horrendous, I can only describe it as suddenly someone just chucking the worst type of flu at you. You 
ache all over, you can’t move, you’ve a raging headache, you just feel like death. I asked the doctor to come off them and 
he put me on Gabapenn. But I just couldn’t even drive on the Gabapenn, you’re just so spaced out. (Male, 45)
And you become more and more dependent and then you become more and more tolerant (Male, 36)
Category 3: Funconal limitaons because of pain
I think the main thing that affects me is probably the pain element and just general discomfort because of where it is. So, 
really, this sounds really stupid. It’s stupid things like I can’t take a bath anymore ‘cause I can’t lean back on the tumour 
site. I can’t sit on the sofa comfortably without propping myself up so I don’t put any pressure. I’ve got one sleeping 
posion I can sleep in. Just ridiculous things like that really. (Female, 38)
Yes, it was, very much.  I just want to act and try and be treated as normal. But certainly the fague and the way it 
affects that, so actually, I suppose, even though I was increasing the painkillers the pain was geng worse and worse 
and worse and that also red me out, made me really irritable, short temper, very moody because you’re just living with 
pain 24/7.  (Male, 40)
The pressure thing and the sensivity is always there. I have to sleep on this side at night now and I have to move my arm 
behind, I have to put my shoulder back so my arm is on my chest because otherwise then I feel the pressure. (Male, 40)
Feel in my armpits. So it’s that movement. And if I’m liing heavy things I get the stabbing pains in some of the... Had to
stop horse riding ‘cause of where they are and just the force of movement and things. Makes it [pain] worse. So, yes, 
another thing that I love that I can’t do now. (Female, 32)
Well, it’s everything. I can’t sit properly. It never goes away. (Female, 28)
It’s just this constant awareness that I must watch walking through the doors or if anybody is on this side that they don’t 
touch me. Somemes, the pain just comes on its own. (Male, 40)
When it was in the bad way I was constantly shielding myself in case you bump into a door, it’s excruciang, escalang, 
on the tube and everything, constantly in that protecve way. Had a young daughter at the me and she come to jump 
at me and I would just be defensive all the me because the pain would be so bad. So that really, the pain did change the 
way I behaved in terms of just walking around, commung or dealing with people.  (Male, 36)
Category 4: Mobility
I used to do a lot of indoor rock climbing. And anything, now, that involves any kind of extension of my shoulders is very 
difficult. So it’s cut off some of my past-mes and things that I used to do in my spare me. (Female, 38)
I find that somemes I get stuck in clothes. I’ve been actually in a changing room before and not been able to get it off. 
‘Cause you think, I should be able to do that. Well, I can’t… Had to stop horse riding ‘cause of where they are and just the 
force of movement and things. Makes it worse. So, yes, another thing that I love that I can’t do now. (Female, 32)
I can’t carry my shopping bag, in my le arm so I get frustrated. I struggle to li and can’t carry my granddaughter.
(Female, 53)
He put his hand out to shake me and I couldn’t li my hand. (Female, 28)
I find it humiliang to ask for help with basic acvies as in that age people are expected to be fully independent and 
able to do everything themselves. (Female, 23)
Subtheme 2: Role limitaons
Category 1: Marital funconing
Well, on a scale of 1 to 10 of cocking my life up, probably at about 9.9 realiscally. My marriage broke up because of all 
the medicaon and the side effects, if you guys know what the side effects of taking the Tamoxifen are and how it makes 
you feel. That’s what drove my marriage down the drain, which was a 20-year marriage. (Male, 40)
It [lack of libido, don’t feeling yourself because of Tamoxifen] affected the relaonship with my wife and everything. 
Luckily she was strong enough and we got through it together but it was my no means easy. (Male, 45)
And you feel like a burden your partner. Because it’s quite... when you’re very down. You’re maybe crying a lot or geng 
very depressed about things. I live with my boyfriend and it’s almost relentless for him. So when I was off for periods 
being sick and he was the first person, the only person I saw every day. And he’d come back from work and I would just 
be... Just unburden on him. And I think that has an effect on relaonships. Because then you feel like, oh, I’m being a 
burden. I need to stop. I need to cope. Because I can’t... (Female, 38)
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Stress has taken a toll on relaonship. I am more irritable with my fiancée, fague is affecng sex life. (Male, 40)
Category 2: Family funconing
‘Cause when he was a baby, his cot, my tumour would hit the side of the cot when I’d to try and get him out and that. So 
it was quite difficult. I could never breaseed him. I didn’t do any of that. (Female, 28)
Had a young daughter at the me and she come to jump at me and I would just be defensive all the me because the 
pain would be so bad. (Male, 36)
I’ve found that with my son as well. When he’s doing imaginaon games and stuff, he takes his lile teddy bears for 
blood tests and things like that. And he’s like, oh, we’re going to hospital. And all of his... And then I feel, oh my God, his 
life has just been my hospital. I do feel awful somemes that that’s his…(Female, 28)
But, ridiculously, I felt like a burden, ‘cause my mum would go on up to hospital with me. She’d spend more me with me. 
So he’d [brother] be le alone. So, at some points, I did aempt to take my life, ‘cause I just felt like a burden. I felt guilty. 
I thought I’m not leng my brother have a childhood or the same treatment asme. (Female, 25)
We are moving with them [parents] now because of my thing. So they can help me with my son. (Female, 32)
Category 3: Job/finances
My job has been changed for me. I can’t classroom teach any more. (Female, 59)
I changed jobs recently to a part me posion as I had a restaurant before and it was too much for me so sold it. (Female, 
53)
Not able to find a new job because pain in hindering. (Male, 40)
I was enforced sick leave. So they wouldn’t let me come back. I was, just on statutory sick pay. Which was less than half 
of what I was earning. So, yes, it was 17emoralizing. ‘Cause all I wanted to do was be back at work. And that’s what 
takes my mind off it. Now. Is being at work and being acve. And so to be told, no, you’ve got to stay at home. And I 
missed out on becoming deputy manager as well because of it. And they actually said to me, well, if you hadn’t been off 
sick, then you would have been deputy by now. (Female, 32)
Financially horrendous, lost my house, everything, because of just not being able to work. I was running quite a successful 
IT company and just the pain and living with the medicaon, and what it does to you across the day, it’s just been really 
difficult.  (Male, 45)
But what impacted me the most was... Because the space between having surgery and radiotherapy, I wasn’t given a car 
to bring me up here. So I was having to travel two hours a day, every single day, on the train. To great expense. I think it
cost me a thousand pounds to travel up here for six weeks. (Female, 28)
The biggest impact with mine was financial. So you think, every single me I was coming up here.... It’s 50 pounds travel.
(Female, 25)
My financial situaon has changed because I had to swop from full-me to part-me job because I was not able to work 
as hard as before. (Female, 23)
I would like to change jobs but feel I am more secure in exisng employment. (Male, 35)
I work extra hours to cover hospital travel costs. (Male, 40)
Subtheme 3: Social funconing
Category 1: Lack of understanding
I was 11 and 12. For me to not understand. My family to not understand. But then have the pressure of my friends saying, 
why are you missing school? Why are you not here? And then not giving me that support from that age is difficult. ‘Cause 
you’re all bonding. You’re geng to secondary school and I was out a lot of that. (Female, 25)
But also going to work. I’m a teacher. And people saying to me... One of the comments was really great. Your 
chemotherapy can’t be very strong ‘cause your hair hasn’t fallen out. That was fabulous. Another one, while we were 
having a teacher training day and I had all this toxicity in my mouth. Couldn’t eat ‘cause it was just so painful. It was full 
of blisters. And they prepared this starter. Actually I said, I’m not going.Because the food was literally falling out of my 
mouth. And I was told I wasn’t a team player. (Female, 59)
I’m not really receiving any acve treatment. We’re just waing to see if it grows. That in terms of other people’s 
percepon of it, I think, unless you’re sort of laid on a bed geng chemotherapy, or you’re off work, or blah, blah, 
everyone thinks you’re fine. And it feels like you’re just suffering a bit from hypochondria. Like it’s not really a thing. So 
everybody’s concern goes away when it’s not malignant. But I think they don’t understand that it’s a daily thing that 
you’re living with and physically and psychologically it’s really tough. And it’s quite difficult to convey that to people, I 
think. (Female, 38)
Socializing has become difficult because of the pain and uncomfortableness. (Female, 28)
Constant fight with people explaining what it is I have. (Female,28 )
Category 2: Social isolaon
Emoonal support and support from friends and colleagues. People stop asking you about it. And somemes you just 
want to talk about it. And somemes you don't. But somemes you do. I think, for me, last year, I became quite shut in. I 
missed out on a whole ton of social occasions. I didn't go to my work party. I didn't go to a whole load of family 
occasions. Because I felt so disturbed by the whole diagnosis. (Female, 38)
I feel quite isolated. It's nice to know other paents here are feeling the same. You feel so alone. (Female, 32)
I can see that in my daily life now. Where my friends area lot more confident than me. And they can speak beer than 
me. They've got a lot more experience behind them. With social scenarios. (Female, 25)
Subtheme 4: Emoonal funconing
(continued)
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Category 1: Living with a chronic disease
But what we're all living with has been life-changing and is lifelong. And has knock-on complicaons for you. (Female, 25)
Mine has become more about the fact that it’s just been my life and no maer what, the professor told me, “No maer 
what we do, you’ll be living with this for the rest of your life. It’s that simple.” He said, “It’s come back again. Even if we 
take it away, it will probably come back again.” (Male, 45)
I guess my psychological demeanour just generally, knowing that I’ve now this probably chronic condion. (Male, 34)
But when they told me that it's coming back, I say, oh, wow, this is a strong. This is not that easy as I thought. And then 
another one [tumour] in less than a month. I say, oh my God, what is going to happen? What is the next thing? This is 
never...Never ending. (Female, 32)
Category 2: Uncertainty around tumor behavior and  fear of recurrence
Somemes it feels bigger, somemes it feels smaller. Yesterday, it actually felt smaller. This morning, I looked at it again 
and it went all the way around the arm again.  I don’t understand how it can change in size that quickly or is it my 
imaginaon or am I going mad? (Male, 40)
But then without having any sort of pressure on it at all, you can just go through big twinges of just that kind of burn
sensaon and no stabbing pains. It just seems really weird. Then that throws you psychologically because you’re like, 
“Well, is it growing?” Or if you haven’t got that, “Is it not growing? Is it reducing in size?”(Male, 40)
Category 3: Mood
And I was so depressed. I was just going down and down and down and down. But you don't really realise 'cause it goes 
very slowly. And then that I really struggled with. Because I knew it was my drugs that made me like it. But I couldn't... I 
need a soluon that doesn't involve drugs. 'Cause this is my life forever. And I can't be in that state forever.(Female, 28)
When I was on Tramadol I got very conspated and when I came off it  very very depressed and emoonal and I was not 
prepared for that. (Female, 53)
The mood swings, I have the mood swings. (Male, 40)
Even though I was increasing the painkillers the pain was geng worse and worse and worse and that also red me out, 
made me really irritable, short temper, very moody. (Male, 40)
I get very red on the medicaon I’m on (Naproxen and Tamoxifen) which makes me irritable and stressed. (Female, 53)
Category 4: Body image
It's also the feeling very conscious that I've got a big lump on my shoulder which, as a woman. And I don't feel 
comfortable having it exposed. So I wouldn't wear a vest top in summer and things like that. And I think that probably 
has a bit of a knock-on effect with my general body image and my sex life with my partner and things like that. So, I 
think, last year I was hit really hard by it. I found it really difficult. (Female, 38)
It changes the way you look as a woman. Because you have to cover it all the me, cover it, cover it… (Female, 32)
But I understand what you're saying about when you're dressing and how you look. Because I'd gone from being a person 
who was always lile tops, whatever. But now I've got this massive... Well, it looks like a route map of Great Britain, 
really. It runs all the way down here. All the way across here. And it's upseng. It just changes your life, yes. 
Dramacally. (Female, 59)
(continued)
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Subtheme 1: Finding your way in the health care system with a rare disease
About being diagnosed with the thing and understanding what it means. What it is. It's so terribly difficult to find out. It 
took me weeks on Google. But not even the word 'desmoid'... What does that... Nobody knows what it means. I know a 
lot of doctors. They say “What?” And then you get onto the whatever it is of rare diseases and so I think that was a huge 
problem for me. What is this thing? (Female, 71)
I think it is because it's such an unknown thing. I've been into hospital while I've had this and had to explain what it is I've 
got. Because automacally look at you. Oh my God, you've got a tumour. And when you tell them they go, oh. I don't 
want to have to explain it every me I come in. And in the end, I actually had a print-out, a sheet, with me. I've had this. 
And I just used to say to them. (Female, 28)
And I think probably in all of our cases, we're probably the only people that our GPs have seen with this condion. And it's
so rare. He had to Google once I got my diagnosis. (Female, 28)
I think one of the worst situaons was dealing with …..[one of the cancer paent support organisaons], of being a 
paent who’s dealing with all the side effects and treatment of cancer and they were like, “You’re not a cancer paent so 
we’re not going to help you.” It put my wife, you know, it made her cry because they just wouldn’t help. We were like, 
“Yes, they must deal with obviously a lot worse situaons and there are paents out there in a lot worse posions,” but it
was very much, for us, we were all dealing with exactly the same symptoms, pain, the output of what the treatment gives 
you and everything. But because it’s not cancer they were like, “We’re not going to help you.” (Male, 40)
I think, personally, find it psychologically quite difficult coming to a cancer hospital and being surrounded by people who 
probably have terminal condions. And coming in with my lile desmoid. And you feel a bit like a fraud. So I do find in my 
consultaons, I'm really aware that they've probably seen somebody who's dying before and aer me. And you don't
want to waste me. And you tend to downplay things. So, personally, from my point of view, being surrounded by other 
desmoid sufferers, would help a lot. Like you say, in the waing room situaon, and if you saw the same faces, that 
would also be quite helpful from my perspecve. (Female, 25)
Subtheme 2: Informaon provision
And I was seen by an orthopaedic surgeon who aer my... I had an appointment aer my diagnosis. And during that 
appointment he asked me what I wanted to do about... And I had literally no informaon about the condion other than 
what I could glean off the internet, which was not very much at all. And, at the me, I just wanted it out. So I said, well, I 
want it removed. So he said, okay, fine. Book you in for surgery. So I le and he said, oh, it'll be between six and 12 weeks 
for the surgery. And when I le the hospital I thought, this feels really strange, 'cause he hasn't told me what the surgery 
would involve. He hasn't told me about recurrence which I now know is a problem. So at that me I didn't know. He didn't 
explain that, basically, it's almost these tumours have like tentacles. So you have to remove a huge margin. In some cases 
on the shoulder, they've had to remove most of the shoulder muscle. That I could be quite disabled aerwards. It could 
recur. All this kind of thing. He never went through anything with it. (Female, 25)
'Cause I was laying on the radiotherapy bed and they said to me, right, you are only 26, at this stage. We think that it's 
going to make you inferle because it's going to obliterate both of your ovaries. They said, do you sll want to go ahead? 
Because, obviously, it's that and it's not cancerous. But if you don't it's not to going to kill the fibral ssue. So it could 
reoccur. And at that me I wasn't... didn't want children. So I said, right, go ahead. I said, if I have to, I'll adopt. If I want 
children. So I done that. My last radiotherapy session was April Fool's Day, year 2010. Three months later, I fell pregnant 
with my son. (Female, 28)
Just a single informaon sheet about fibromatosis. There isn't one. (Female, 59)
A leaflet with informaon would be really helpful as I had never heard of it before diagnosis. I was told by the doctor to 
Google it! I would be beer to have a hand out with descripon of what it is and ps on how to help it e.g. keep out of 
the sun, use ice and any other ps that would help. Maybe a picture of what it looks like. (Female, 53)
Subtheme 3: Connuity of care
The only difficulty I found here, was that every me we came in, I always saw a different person each me. I know it’s all 
part of the mul-discipline team and everything like that, but it’ll be with Dr A and then Dr B and then someone else. It 
was never one point of contact, but it always felt that you always had to explain again your circumstances because 
they’d have your notes but they might not have been dealing with it. That to me was probably the most frustrang thing 
because, even though obviously it was apparent that your case was discussed and people did know your situaon, 
probably not fully but it was always like, “Who are we going to see today?”, “Do they really know my full story and 
background?”And with that it became more of a risk of having different recommendaons given to you. It would be, “Oh, 
in my opinion you should do this,” or, “We’re thinking of doing chemotherapy,” or, “Actually, we’re thinking of keeping 
you on the Tamoxifen for another three months,” whatever. (Male, 40)
When you get into this complicated situaon, you don't know what's causing what and why you're feeling like you are. 
And a session with a professional counsellor who's knowledgeable about the whole drug scene would be really good me 
spent. (Female, 71)
Subtheme 4: Peer support
I am seriously overwhelmed to see all of you with the same disease as me. I live nearly 11 years with this disease and 
thought I was the only one. (Female, 32)
For me personally, me being out and to know that there are other people that are living with this condion, and being 
able to potenally have contact with these people, would be really useful and comforng. And also I think we probably all 
feel like we’re out there on our own a lile bit and it’s nice to know that you’ve got possibly some other people that you 
know you can count on your support when maybe mes are a lile bit tough.  (Male, 45)
But again, mirroring what the guys were saying here, being able to speak with people who are dealing with the same 
disease, it’s a chronic illness, and so lile is known about it, but it’s really valuable to hear their stories. You feel unique in 
some respects and it’s good to hear what other people are going through and you’re not really the only one. And being 
able to potentially help people who are at earlier stages in the treatment to hearing from people who are further down 
the line, is mentally valuable.  (Male, 40)
An online support or chat group or something would really validate your experience. It validates what you've been 
through. (Female, 25)
Appendix 4: Quotes theme 4—supportive care
Support Care Cancer (2019) 27:965–980 977
1. Introductory remarks to explain the nature and pur-
pose of the study.
Good afternoon/evening. Thank you for taking the time to
join our discussion on the supportive care needs of patients
w i t h d e s m o i d f i b r o m a t o s i s . M y n a m e i s
_ _ _ _MODERATOR_ _ _ _ , a n d I am _ _ASST
MODERATOR____.
In particular, we hope to learn more about the physical,
psychosocial and practical challenges you face as a desmoid
fibromatosis patient and on how your experience has been of
the healthcare system: What kinds of things have been helpful
to you and what kinds of things you might have wanted or
needed but did not receive.
Before we begin, let me suggest some things to make our
discussionmore productive. Because we’ll be recording for an
accurate record, it is important that you speak up and that you
only speak one at a time. We do not want to miss any of your
comments. We’ll only use first names here. No reports will
link what you say to your name. In this way, we will maintain
your confidentiality. In addition, we ask that you also respect
the confidentiality of everyone here. Please do not repeat who
said what when you leave this room. During the two hours
we’ll be here, I will ask you questions, and I will listen to what
you have to say. I will not participate in the discussion. So
please, feel free to respond to each other and to speak directly
to others in the group.We want to hear from all of you.We are
interested in both majority and minority viewpoints, common
and uncommon experiences. So I may sometimes act as a
traffic cop by encouraging someone who has been quiet to
talk, or by asking someone to hold off for a few minutes.
Does anyone have a problem with audio recording of this
focus group? Okay, then we will turn on the recorder and start
now.
2. Introduction participants.
First of all, can you briefly introduce yourself (first name,
age, tumour localisation, treatment received).
3. Main open-ended questions CHALLENGES.
-When we think about your health, what would you say the
term quality of life means to you?
* What factors would you say contribute to your quality of
life?
*Which factor would you say is / are the most important to
you?
-With that in mind, in what ways has your desmoid
fibromatosis diagnosis affected your quality of life?
-With that in mind, in what ways has your treatment for
desmoid fibromatosis diagnosis affected your quality of life?
-With that in mind, in what ways has the watch and wait
policy affected your quality of life?
PROBE AS NECESSARY:
e.g. in these areas, how has it affected you….
-Physically: e.g. symptoms… .. how?
-Functionally: e.g. ability to get about / wash / dress ….
How?
-Psychologically: e.g. feeling worried/ stressed / tense…..
How?
-Socially: e.g. impact on relationships, social life
…….How.
- Other: (Financial/ Spiritual).
-Could you tell me more about that and how you deal(t)
with challenges/problems?
-What would you say has been the most important / biggest
factor(s) influencing your quality of life since your diagnosis?
-What is the meaning of symptoms for you in relation to
disease activity (e.g. fear of progression) and response to
treatment?
4. Main open-ended questions (UNMET) CARE
NEEDS.
-I would like to ask you to talk about the various needs you
have as a desmoid fibromatosis patient. -What has your expe-
rience been with receiving healthcare services/supportive care
for your desmoid fibromatosis?
PROBE AS NECESSARY:
What was good about that care you received till now?
Why?
What was bad about the care you received till now? Why?
What did you miss? Why?
What is your experience with referral to supportive care
and use of supportive care options?
-I’ll now ask you to talk about your needs for a number of
different areas. I would be interested to learn for each area
whether you have needs in this area and whether or not your
needs have been addressed (what is/was helpful and what is/
was missing).
Informational needs.
Psychological/Emotional needs positive and negative.
Physical needs.
Risk behaviour needs.
Practical needs.
Social needs.
Spiritual needs.
Health care needs.
5. Main open-ended questions EXPECTATIONS AND
PREFERECES.
-What are your expectations of care for patients with
desmoid fibromatosis?
-What are your preferences for care for patients with
desmoid fibromatosis?
PROBE AS NECESSARY:
If you could design the perfect expert center for desmoid
fibromatosis patients what would it look like for patients that
are undergoing treatment? What would it look like patients in
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watch and wait phase? Please be as creative as possible as we
are interested in your ideas.
What kind of programs would be helpful to you in dealing
with the challenges of desmoid fibromatosis?
What formats are you most interested in? Would you prefer
groups, individual, face-to-face, online, or a combination?
6. Summarise the issues raised during the interview and
identify which issues are the most important.
-We have discussed a number of things. These are…
MODERATOR SUMMARISES POINTS…..
-Out of everything we have talked about today, what are
your top three needs and how could they be better met?
- Is there anything else about needs related to desmoid
fibromatosis that you can think of that we have not already
discussed?
Thank you again for taking the time to participate in this
discussion.
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